Telocyte’s founder and president, Michael Fossel, has recently published a highly influential paper in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association which was called by the editors as “the most important article we have ever published.” The paper already has had more than 300 requests for reprints. This article not only explains why telomere- based theories of ageing are the future in modern biogerontology, but also delivers the most up- to-date characterization of pathophysiology of Alzheimer’s disease (AD). Telocyte’s gene therapy developed for AD, and supported by Babu™, can be better understood with the rationale within Dr. Fossel’s article that can be found here. ![]()
Comments are closed.
|
1/17/2020